Lexeo prices $135M offering; FDA open to faster LX2006 approval path

Lexeo Therapeutics, Inc.

Priced public offering of 15.625M shares at $8.00 and $10M private placement (pre-funded warrants) to Balyasny; gross proceeds ~$135M.
Preliminary cash, cash equivalents and investments of $122.8M as of Sept 30, 2025.
FDA indicated openness to accelerated BLA for LX2006 using pooled Phase I/II and pivotal study data; enhanced manufacturing comparability required.
LX2006 interim data: sustained or deepening improvements in LVMI and frataxin in majority of 16 participants at >=6 months follow-up.
LX2020: 9 participants dosed; one Grade 3 SVT resolved; low-dose cohort shows stable cardiac parameters; more data expected Jan 2026.

item 1.01 item 2.02 item 3.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.95

Lexeo Therapeutics, Inc. issued 15,625,000 shares of Common Stock, plus an over-allotment option for up to 2,343,750 additional shares of common stock to the several underwriters for gross proceeds of approximately $125 million, at a price to the public of $8.00 per share, underwriter purchase price $7.52 per share.

Security: common stock
Shares: 15,625,000 shares of Common Stock, plus an over-allotment option for up to 2,343,750 additional shares
Purchaser: the several underwriters
Consideration: gross proceeds of approximately $125 million, at a price to the public of $8.00 per share, underwriter purchase price $7.52 per share

Exact text from the filing

On October 16, 2025, Lexeo Therapeutics, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Leerink Partners LLC, as representative (the “ Representative ”) of the several underwriters named therein (collectively, the “ Underwriters ”), relating to the issuance and sale in a public offering (the “ Public Offering ”) of 15,625,000 shares (the “ Firm Shares ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), at a price to the public of $8.00 per share.

View on SEC.gov

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.95

Lexeo Therapeutics, Inc. issued pre-funded warrants to purchase 1,250,015 shares of Common Stock of warrant to a qualified institutional buyer for aggregate gross proceeds of approximately $10 million, at $7.9999 per Pre-Funded Warrant.

Security: warrant
Shares: pre-funded warrants to purchase 1,250,015 shares of Common Stock
Purchaser: a qualified institutional buyer
Consideration: aggregate gross proceeds of approximately $10 million, at $7.9999 per Pre-Funded Warrant

Exact text from the filing

“ Public Offering ”) of 15,625,000 shares (the “ Firm Shares ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), at a price to the public of $8.00 per share. Under the terms of the Underwriting Agreement, the Underwriters have agreed to purchase the Firm Shares from the Company at a price of $7.52 per share. In addition, the

View on SEC.gov

Browse all equity issuances →

Lexeo Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-242652

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.